trastuzumab

all catalysts(0)

nothing on the calendar yet

News(10)

• ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
  When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
  fiercebiotech · 3d ago
• Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
  Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.
  fiercebiotech · 8d ago
• Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
  Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
  biospace · 1mo ago
• New Jazz cancer drug approval could drive blockbuster sales
  Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
  biopharma_dive · 1mo ago
• After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
  One of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.
  fiercebiotech · 2mo ago
• A Spanish biotech banks $87M to make differentiated ADCs
  Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
  biopharma_dive · 4mo ago
• FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer
  The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.
  onclive · 4mo ago
• Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
  Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.
  onclive · 4mo ago
• Sequencing ADCs in Endometrial Cancer
  Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.
  onclive · 4mo ago
• Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
  Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
  onclive · 4mo ago